{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:11:04Z","timestamp":1793326264434,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["Horizon 2020 ERC-2020-CoG 101001866-INSPIRE"],"award-info":[{"award-number":["Horizon 2020 ERC-2020-CoG 101001866-INSPIRE"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ard.2026.05.023","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:07:10Z","timestamp":1781842030000},"page":"2194-2207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis\u2014a case series"],"prefix":"10.1016","volume":"85","author":[{"given":"Elise","family":"Siegert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpida","family":"Phithak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2697-9080","authenticated-orcid":false,"given":"Fredrik N.","family":"Albach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman Michael","family":"Drzeniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dzamukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Schleser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Chiara","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Trezzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria Claire","family":"Rein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Marisa","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Doellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Staeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Sinzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Unterwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ohrndorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaosi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thula","family":"Walter-Rittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Luise","family":"H\u00fctter-Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Pecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Troldborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Erika","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.05.023_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxae098","article-title":"The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies","volume":"219","author":"Scaletti","year":"2025","journal-title":"Clin Exp Immunol."},{"issue":"26","key":"10.1016\/j.ard.2026.05.023_bib0003","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ard.2026.05.023_bib0004","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med."},{"issue":"25","key":"10.1016\/j.ard.2026.05.023_bib0005","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.ard.2026.05.023_bib0006","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med."},{"issue":"7","key":"10.1016\/j.ard.2026.05.023_bib0007","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"24","key":"10.1016\/j.ard.2026.05.023_bib0008","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"Jama."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ard.2025.08.021","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease","volume":"85","author":"Antoniou","year":"2026","journal-title":"Ann Rheum Dis."},{"issue":"9790","key":"10.1016\/j.ard.2026.05.023_bib0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"10.1016\/j.ard.2026.05.023_bib0013","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"10.1016\/j.ard.2026.05.023_bib0014","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.ard.2026.05.023_bib0015","first-page":"100008","article-title":"CD19-targeting CAR T cell therapy in five patients with systemic sclerosis unsuitable for autologous stem cell transplantation","author":"Pecher","year":"2025","journal-title":"EULAR Rheumatol Open"},{"issue":"9","key":"10.1016\/j.ard.2026.05.023_bib0016","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med."},{"issue":"15","key":"10.1016\/j.ard.2026.05.023_bib0017","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N Engl J Med."},{"issue":"16","key":"10.1016\/j.ard.2026.05.023_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell."},{"issue":"4","key":"10.1016\/j.ard.2026.05.023_bib0019","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"10.1016\/j.ard.2026.05.023_bib0020","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","article-title":"Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases","volume":"32","author":"D\u00fcsing","year":"2026","journal-title":"Nat Med."},{"issue":"5","key":"10.1016\/j.ard.2026.05.023_bib0021","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.05.023_bib0022","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ard.2026.05.023_bib0023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.ard.2026.05.023_bib0024","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41409-025-02684-1","article-title":"Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation","volume":"60","author":"Del Papa","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"10.1016\/j.ard.2026.05.023_bib0026","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0027","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ard.2025.09.012","article-title":"Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome","volume":"85","author":"Phithak","year":"2026","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"10.1016\/j.ard.2026.05.023_bib0028","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ard.2025.05.007","article-title":"One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease","volume":"84","author":"Lorenz","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.ard.2026.05.023_bib0029","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med."},{"issue":"6","key":"10.1016\/j.ard.2026.05.023_bib0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer."},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.05.023_bib0044","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1182\/blood-2025-718","article-title":"Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed\/refractory multiple myeloma; Results from the Danish ABCD study","volume":"146","author":"Torpe","year":"2025","journal-title":"Blood"},{"issue":"2 Suppl 76","key":"10.1016\/j.ard.2026.05.023_bib0031","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol."},{"issue":"6","key":"10.1016\/j.ard.2026.05.023_bib0032","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/sarh.2001.21904","article-title":"Pulmonary-renal syndrome in systemic sclerosis","volume":"30","author":"Bar","year":"2001","journal-title":"Semin Arthritis Rheum."},{"issue":"9872","key":"10.1016\/j.ard.2026.05.023_bib0033","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.ard.2026.05.023_bib0034","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","article-title":"Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners","volume":"52","author":"Farge","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.ard.2026.05.023_bib0035","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ard.2026.05.023_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.ard.2026.05.023_bib0037","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.41085","article-title":"Using transitional changes on high-resolution computed tomography to monitor the impact of cyclophosphamide or mycophenolate mofetil on systemic sclerosis-related interstitial lung disease","volume":"72","author":"Kim","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"19","key":"10.1016\/j.ard.2026.05.023_bib0038","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA."},{"issue":"9","key":"10.1016\/j.ard.2026.05.023_bib0039","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/s41590-024-01934-6","article-title":"Tracing the origins of lung fibrosis","volume":"25","author":"Buckley","year":"2024","journal-title":"Nat Immunol."},{"issue":"10038","key":"10.1016\/j.ard.2026.05.023_bib0040","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet."},{"issue":"Si","key":"10.1016\/j.ard.2026.05.023_bib0041","doi-asserted-by":"crossref","first-page":"Si114","DOI":"10.1093\/rheumatology\/keae716","article-title":"Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial","volume":"64","author":"Kuzumi","year":"2025","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0042","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13075-020-02360-3","article-title":"Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.ard.2026.05.023_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66974-4","article-title":"Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial","volume":"16","author":"Matsuda","year":"2025","journal-title":"Nat Commun."},{"issue":"6","key":"10.1016\/j.ard.2026.05.023_bib0045","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ard.2026.02.002","article-title":"Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series","volume":"85","author":"Scherlinger","year":"2026","journal-title":"Ann Rheum Dis."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726003018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:07:07Z","timestamp":1793282827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726003018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0003496726003018"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.023","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis\u2014a case series","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}